

Over Half a Day Shorter LOS, Nearly \$1M in Savings

COREWELL HEALTH WEST'S
DKA ROI UNCOVERED

Case Study

THE CUSTOMER

Corewell Health West, a leading healthcare system in Michigan, used EndoTool IV, a patient-specific computerized insulin dosing system since 2009 to support safe, effective glycemic management and improve hospital efficiency.

In recent years, Corewell Health West experienced a 20% rise in Diabetic Ketoacidosis (DKA) admissions, reflecting a broader national trend of a 55% increase over the past decade. While the system had already achieved strong outcomes, clinical leaders sought to understand the value their approach was delivering in the face of growing demand.

To answer this, Corewell Health West conducted a retrospective analysis of DKA patient outcomes and care efficiency across their system.

Challenge

Corewell Health West set out to evaluate the impact of EndoTool IV on DKA patient outcomes with a focus on:

- Reducing inpatient length of stay (LOS) to lower costs and increase capacity.
- Improving clinical outcomes, including mortality and hypoglycemia rates.
- Decreasing the cost of care per DKA patient.

Review

A retrospective study evaluated DKA patients treated at Corewell Health West from **January 2023 to June 2024**.

Corewell Health West's outcomes with EndoTool IV were benchmarked against risk-adjusted expected outcomes from the Vizient Clinical Data Base and an internal comparison group of 115 academic medical centers.



“By treating all of our DKA patients with EndoTool, we were able to reduce the cost of care by \$1,200 per patient and shorten hospital stays. Outcomes that other hospitals have been unable to achieve without EndoTool.”



Gregory Deines, DO
Division Chief of Diabetes and
Endocrinology, Corewell Health West


Better outcomes, lower cost

Corewell Health West achieved better clinical and financial outcomes with EndoTool IV. They reduced hospital stays and costs, lowered mortality, and improved ICU efficiency while virtually eliminating severe hypoglycemia.

How actual outcomes surpassed expectations

Metric	Actual Outcomes	Expected Outcomes	Impact
LOS (all patients)	5.15 days	5.82 days	514 hospital days saved
Mortality	2.3%	3.2%	6 fewer deaths
Cost per DKA Patient	\$8,125	\$9,329	\$1,204 saved per patient
Severe Hypoglycemia	0.006%	Not measured	Extremely low risk
ICU Utilization	85%	49%	Efficient high-acuity care





EndoTool IV enabled Corewell Health West to deliver higher-quality care at a lower cost, demonstrating clear ROI even in high-acuity settings.



A strategic framework for reducing LOS and driving ROI

Corewell Health West's implementation of EndoTool IV proves patient-specific insulin dosing achieves significant clinical improvements while generating meaningful financial returns.

By shortening total hospital stays, and saving over \$1,200 per patient, Corewell Health West avoided more than \$900K in direct costs in high acuity settings over the 18 month period.

For healthcare leaders seeking to improve care quality and financial performance simultaneously, Corewell Health West's experience offers a compelling, databacked example of how patient-specific insulin management leads to stronger outcomes and operational efficiency where it matters most.



Why leading health systems trust EndoTool

EndoTool is the only patient-specific insulin dosing software, designed to improve glycemic management with realtime adaptability and advanced safety features. EndoTool prevents insulin stacking and hypoglycemia by precisely calculating every dose using multiple clinical factors like kidney function and past insulin administration, offering a level of accuracy unmatched by any other system or protocol. Backed by 50+ independent, peer-reviewed studies, EndoTool is FDA-cleared, fully integrates with major EHRs, and is trusted by top hospitals nationwide. See why leading health systems rely on [EndoTool](#).

REFERENCES

1. McCoy RG, Herrin J, Galindo RJ, et al. Rates of hypoglycemic and hyperglycemic emergencies among U.S. adults with diabetes, 2011–2020. *Diabetes Care* 2023;46:e69–e71
2. Benoit SR, Zhang Y, Geiss LS, Gregg EW, Albright A. Trends in diabetic ketoacidosis hospitalizations and in-hospital mortality – United States, 2000–2014. *MMWR Morb Mortal Wkly Rep* 2018;67:362–365



Experience the
future of care
with EndoTool's
patient-specific
insulin dosing.

Transforming diabetes across the full continuum of care



ABOUT GLOOKO

Glooko is a global portfolio of companies advancing intelligent connected diabetes and glycemic care across the care continuum. Through its offerings, Glooko is the only organization delivering integrated support from hospital to home. Together, these capabilities empower patients, healthcare providers, and health systems with data-driven tools that improve outcomes, simplify workflows, and scale care across inpatient and outpatient care settings.

[Glooko.com](https://glooko.com) | [MonarchMedTech.com](https://monarchmedtech.com)

EndoTool is developed and marketed by Monarch Medical Technologies, a Glooko Company. EndoTool is an FDA-cleared Class II medical device indicated for inpatient use as described in its Instructions for Use. Glooko's diabetes management platform and EndoTool are currently independent solutions. Patient-specific refers to EndoTool's ability to use available patient information within the hospital's electronic medical record to provide individualized insulin dosing recommendations. Recommendations are intended to assist, not replace, clinical judgment. All treatment decisions remain the responsibility of the licensed healthcare provider.